ERIS share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on ERIS. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for ERIS is 71 out of 100 as of 21 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for ERIS is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

ERIS sits in Healthcare (mid cap), indicative market cap ~19,916 cr (indicative), ISIN INE406M01024. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, ACUTAAS CHEMICALS LIMITED, IPCA LABORATORIES LIMITED. A systematic, data-only read on Eris Lifesciences Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on ERIS is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, Eris Lifesciences Limited sits in the Near-perfect tier with a setup score of 99/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 16 ERIS earnings calls going back to 2021-10-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

Eris Lifesciences Limited reported a net profit of Rs 279 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +172.7% year on year, a move distorted by a prior-year base effect. The figure is from the company's official NSE filing.

Eris Lifesciences Limited reported revenue of Rs 757 cr for Q4 FY26. That is +7.3% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives Eris Lifesciences Limited's Q4 FY26 result a Result Pulse of 93 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Eris Lifesciences Ltd's two most material recent disclosures are a regulatory dated 09 Jul 2026, "Certificate under SEBI (Depositories and Participants)…", and an insider trade dated 26 Jun 2026, "the Trading Window closure pursuant to SEBI (Prohibition…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Eris Lifesciences Ltd filed a dividend disclosure on 29 May 2026, filed as "Interim Dividend - Rs 7.21 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Eris Lifesciences Ltd's most recent board-meeting disclosure on record dated 20 May 2026 reads "Board Meeting to be held on 20-May-2026 to consider and approve the…". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.

Eris Lifesciences Ltd filed a credit-rating disclosure on 12 May 2026, recorded with the exchange as "Credit Rating of Eris Therapeutics Limited". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.